High levels of β2-microglobulin in MM patients, reflect a high tumor burden, renal dysfunction, and turnover of malignant plasma cells, given that β2-microglobulin forms part of the MHC class I molecules expressed on the surface of all nucleated cells, including myeloma cells [31]. Here, HLA-G is linked to plasma cell myeloma.